RxDoctor Payments Data

Ronald Gardner, MD

Orthopaedic Surgery · Fort Myers, FLNPI 1255334488

Payments from drug & device makers

$99,009in general payments, 2019–2025

Across 191 payments — averaging $518.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shalby Advanced Technologies, Inc.$49K
  • Tracpatch Health, Inc$21K
  • Aesculap Implant Systems, LLC$16K
  • Avanos Medical$7K
  • Curonix LLC$1K
  • Microport Orthopedics Inc$912
  • plus $4K from 30 others
$28,050in research payments, 2019–2025

Across 1 payment — averaging $28,050 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • ASA Srl$28K

What the payments were for

  • Consulting fees$73,95775%
  • Speaking & faculty fees$12,05712%
  • Travel & lodging$5,3405%
  • Food & beverage$7,5358%
  • Education$1210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$99,009 in reported general payments places this provider in the 85th percentile of 1,263 orthopaedic surgery providers in Florida.

See all orthopaedic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$514,909
Medicare patients
881
Services billed
4,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib740$19,151
XareltoRivaroxaban13$3,227
Cephalexin578$2,521
Oxycodone Hcl325$2,239
Allopurinol229$1,777
Meloxicam503$1,420
Tramadol Hcl213$1,374
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen99$1,180
Ondansetron OdtOndansetron161$1,116
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen136$765
Fentanyl14$687
Gabapentin76$611
Cyclobenzaprine Hcl76$473
Clindamycin Hcl110$462
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$142$3,22713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,263 orthopaedic surgery providers in Florida.

Other orthopaedic surgery in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →